GRDN — Guardian Pharmacy Services, Inc.

Guardian Pharmacy (GRDN) Q3 2025 Earnings Call Summary

1. Key Financial Results and Metrics

• Revenue: Increased by 20% year-over-year to $377.4 million.
• Adjusted EBITDA: Rose 19% to $27.3 million, with margins holding steady at 7.2%.
• Adjusted EPS: Reported at $0.25.
• Resident Count: Grew 13% to 203,766 residents.
• Gross Profit: Increased to $74.7 million, achieving a margin of 19.8%.
• Cash Position: Ended the quarter with $36 million in cash, up $18 million despite acquisition expenditures.

2. Strategic Updates and Business Highlights

• Public Company Milestone: Celebrated the first full year as a publicly traded company, emphasizing commitment to disciplined growth and shareholder trust.
• Acquisitions: Recent acquisitions in Oregon and Washington are expected to enhance market presence and contribute to growth in the Pacific Northwest.
• Operational Focus: Continued investment in pharmacy leaders and local operators to drive performance and profitability.
• Market Share: Holds a 13% national market share in assisted living facilities, with some pharmacies exceeding 40% market share in local markets.
• Vaccination Program: Vaccine activity remains strong, with a notable early start to the clinic season.

3. Forward Guidance and Outlook

• 2025 Revenue Guidance: Raised to $1.43 billion - $1.45 billion, up from $1.39 billion - $1.41 billion.
• Adjusted EBITDA Guidance: Increased to $104 million - $106 million, from $100 million - $102 million.
• Q4 Expectations: Anticipates steady resident count and slight improvement in margins due to seasonal vaccine activity.

4. Bad News, Challenges, or Points of Concern

• Policy Environment: The Inflation Reduction Act continues to pose challenges, with ongoing efforts to navigate and advocate for favorable outcomes.
• Margin Dilution: Recent acquisitions and greenfield startups are dilutive to overall margins, with expectations for continued pressure in the short term.
• Tax Rate: Reported income tax expense was elevated at 42%, expected to normalize to the high 20s in Q4 and mid-20s in 2026.
• Market Dynamics: The healthcare market is experiencing turmoil, particularly in Medicare Part D, which may affect operational stability and revenue predictability.

5. Notable Q&A Insights

• Vaccine Program: Management noted steady uptake in vaccinations, with a stronger September compared to the previous year, despite broader concerns about vaccine hesitancy.
• Acquisition Impact on Margins: The CFO highlighted that newer acquisitions are still dilutive to margins, but mature pharmacies are performing well, indicating a potential for margin improvement over time.
• Medicare Part D Changes: Management is cautiously observing the impact of recent changes in Part D plans, with no significant shifts noticed yet in drug consumption patterns or plan preferences among residents.
• Operational Capacity: There are no current bottlenecks in executing acquisitions, and the pipeline remains robust, although the pace of acquisitions may moderate compared to previous years.

This summary encapsulates the key aspects of Guardian Pharmacy's Q3 2025 earnings call, reflecting both the company's achievements and the challenges it faces in the current market landscape.